First Patient in China Receives ALS Targeted Therapy Injection at Peking University Third Hospital

Author: Tang Lu

https://www.puh3.net.cn/info/1971/154331.htm

        On June 10, 2025, 43-year-old Ms. Li received Tofersen injection intrathecal treatment via lumbar puncture at the Department of Neurology, Peking University Third Hospital. This marked the first prescription nationwide for Tofersen injection, a targeted therapy drug for Amyotrophic Lateral Sclerosis (ALS), after its official commercial launch in China. This signifies that China's first disease-modifying treatment drug for adult ALS caused by superoxide dismutase 1 (SOD1) gene mutation has been officially applied in clinical practice, bringing new hope for source intervention in the treatment of this rare disease.

Patient Receives Injection Treatment at Peking University Third Hospital